Astellas Pharma Inc.
Clinical trials sponsored by Astellas Pharma Inc., explained in plain language.
Global pharmaceutical company developing medicines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye injection aims to slow vision loss from Age-Related macular degeneration Results expected Jun 2027 (estimated)
-
New eye injection aims to slow vision loss from Age-Related macular degeneration
Disease control OngoingThis study tests the safety of a drug called ASP3021 (avacincaptad pegol) for people in Japan with geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. Twenty participants will receive monthly injections into the affected eye for 12 mo…
Phase 4 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New targeted therapy shows promise in Tough-to-Treat leukemia
Disease control OngoingThis study tested a new drug called ASP2215 against standard chemotherapy in 276 adults with a specific type of acute myeloid leukemia (FLT3-mutated) that had come back or not responded to initial treatment. The goal was to see if ASP2215 helped people live longer (overall surviv…
Phase 3 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC